A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Clinical trial NCT04293562 · RECRUITING
Trial details
- NCT number
- NCT04293562
- Sponsor
- Children's Oncology Group
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-21
- Primary completion
- 2029-06-30
- Enrollment
- 1186
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.